UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

(Amendment No. 6)

CUREVAC N.V. (Name of Issuer)

Common Shares, par value €0.12 per share

(Title of Class of Securities)

N2451R105

(CUSIP Number)

Brian S. North, Esquire Buchanan Ingersoll & Rooney PC 50 South 16th Street, Suite 3200 Philadelphia, PA 19102 (215) 665-8700

Dr. Marc Hauser RITTERSHAUS Harrlachweg 4 · 68163 Mannheim Germany +49 621 4256-275

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

November 8, 2022

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. \Box

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. *See* §240.13d–7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the Notes).

1.				ng Persons. Tech holding GmbH & Co. KG
2.	Check (a) (b)	the App	prop	oriate Box if a Member of a Group (See Instructions)
3.	SEC U		У	
4.	Source OO	of Fun	ds	
5.	Check	if Discl	losu	re of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e)
6.	Citizen Germ a	_	Pla	ce of Organization
		•	7.	Sole Voting Power 0
Numb Shares Benefi		;	8.	Shared Voting Power 70,846,532 ⁽²⁾
Owned Each Report	ing	!	9.	Sole Dispositive Power 0
Person	With	1	١٥.	Shared Dispositive Power 70,846,532 ⁽²⁾
11.	Aggreg 70,846	-	ıouı	nt Beneficially Owned by Each Reporting Person
12.	Check	if the A	∆ggr	regate Amount in Row (11) Excludes Certain Shares (See Instructions) \Box
13.	Percen		ıss F	Represented by Amount in Row (11)
14.	Type o	f Repor	rting	g Person (See Instructions)
Ca Ba Pe	apital Gr eteiligun ersons").	nbH & gen"), i dievini	Co. Zwe i, D	is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-LKG ("DH-Capital"), DHFS II Holding GmbH & Co. KG ("DHFS II Holding"), OH Beteiligungen GmbH& Co. KG ("OH eite DH Verwaltungs GmbH ("Zweite DH"), Dietmar Hopp, Oliver Hopp, and Daniel Hopp (collectively, the "Reporting H-LT-Investments, and Dietmar Hopp are parties to the agreements with KfW described in Item 6 of this Schedule 13D relating to ition of the common shares of the Issuer.
(2) R	epresent	s 70,840	6,53	32 shares held of record by dievini.
				lculated based on 187,120,718 common shares of CureVac N.V. outstanding as reported in its Form 20-F Annual Report filed with change Commission on April 28, 2022

1.				ing Persons. ents GmbH
2.	Check	\boxtimes (1)		priate Box if a Member of a Group (See Instructions)
	(b)			
3.	SEC U	Jse On	ıly	
4.	Sourc OO	e of Fu	ınds	
5.	Check	k if Dis	closu	are of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) \Box
6.	Citize Germ	-	or Pla	nce of Organization
			7.	Sole Voting Power 0
Share Benef	icially		8.	Shared Voting Power 10,102,286 ⁽²⁾
Owne Each Repor	ting		9.	Sole Dispositive Power 0
Perso	n With		10.	Shared Dispositive Power 10,102,286 ⁽²⁾
11.		egate A 2,286 (2		nt Beneficially Owned by Each Reporting Person
12.	Check	s if the	Aggı	regate Amount in Row (11) Excludes Certain Shares (See Instructions) \Box
13.	Percer		lass I	Represented by Amount in Row (11)
14.	Туре (ОО	of Rep	ortin	g Person (See Instructions)
C B P th	Capital G Seteiligu ersons") ne voting	mbH & ngen")). dievi g and d	& Co , Zwo ni, D lispos	s filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH KG ("DH-Capital"), DHFS II Holding GmbH & Co. KG ("DHFS II Holding"), OH Beteiligungen GmbH& Co. KG ("OH eite DH Verwaltungs GmbH ("Zweite DH"), Dietmar Hopp, Oliver Hopp, and Daniel Hopp (collectively, the "Reporting H-LT-Investments, and Dietmar Hopp are parties to the agreements with KfW described in Item 6 of this Schedule 13D relating to sition of the common shares of the Issuer. The Reporting Persons other than dievini, DH-LT-Investments, and Dietmar Hopp atus as a "group" for purposes of this Schedule 13D.
2) R	epresen	ts shar	es he	ld of record by DH-LT-Investments GmbH.
				clculated based on 187,120,718 common shares of CureVac N.V. outstanding as reported in its Form 20-F Annual Report filed with schange Commission on April 28, 2022.

1.				ing Persons. bH & Co. KG
2.	Check			priate Box if a Member of a Group (See Instructions)
	(b)	$\Box^{(1)}$)	
3.	SEC 1	Use Or	nly	
4.	Source OO	e of Fu	ınds	
5.	Check	k if Dis	sclosı	are of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) \Box
6.	Citize Gern	_	or Pla	ace of Organization
			7.	Sole Voting Power 0
Share Bene	ficially		8.	Shared Voting Power 70,846,532 ⁽²⁾
Each Repo	ed by rting on With		9.	Sole Dispositive Power 0
reiso	ii vvitii		10.	Shared Dispositive Power 70,846,532 ⁽²⁾
11.		egate <i>A</i> 6 ,532 (3		nt Beneficially Owned by Each Reporting Person
12.	Check	k if the	Agg	regate Amount in Row (11) Excludes Certain Shares (See Instructions) \square
13.	Perce. 37.9 %		Class 1	Represented by Amount in Row (11)
14.	Type PN	of Rep	ortin	g Person (See Instructions)
G F t	Capital Capita	GmbH (ingen")). dievi g and (& Co), Zw ini, D lispos	s filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH KG ("DH-Capital"), DHFS II Holding GmbH & Co. KG ("DHFS II Holding"), OH Beteiligungen GmbH& Co. KG ("OH eite DH Verwaltungs GmbH ("DH Zweite"), Dietmar Hopp, Oliver Hopp, and Daniel Hopp (collectively, the "Reporting bH-LT-Investments, and Dietmar Hopp are parties to the agreements with KfW described in Item 6 of this Schedule 13D relating to sition of the common shares of the Issuer. The Reporting Persons other than dievini, DH-LT-Investments, and Dietmar Hopp ratus as a "group" for purposes of this Schedule 13D.
2) F	Represen	its 70,8	346,5	32 shares held of record by dievini.
				alculated based on 187,120,718 common shares of CureVac N.V. outstanding as reported in its Form 20-F Annual Report filed with schange Commission on April 28, 2022.
				4

1.	 Names of Reporting Persons. OH Beteiligungen GmbH & Co. KG Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ 				
2.					
	(b))	$\square^{(1)}$		
3.	SE	C Us	e Only		
4.	Sor O(of Funds		
5.	Ch	ieck i	f Disclos	ure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) \Box	
6.		tizens ermai	-	ace of Organization	
			7.	Sole Voting Power 0	
Shar	iber of es eficiall		8.	Shared Voting Power 70,846,532 ⁽²⁾	
Own Each Repo	ed by orting		9.	Sole Dispositive Power 0	
Pers	on Wit	th	10.	Shared Dispositive Power 70,846,532 ⁽²⁾	
11	_	-	nte Amou 532 ⁽²⁾	unt Beneficially Owned by Each Reporting Person	
12	. Ch	ieck i	f the Agg	gregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13		rcent .9% ⁽³		Represented by Amount in Row (11)	
14	. Tyj	-	Reportir	ng Person (See Instructions)	
	Capita Beteili Persor the vo	al Gm igung ns"). o ting a	bH & Co en"), Zw lievini, I and dispo	is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-D. KG ("DH-Capital"), DHFS II Holding GmbH & Co. KG ("DHFS II Holding"), OH Beteiligungen GmbH& Co. KG ("OH veite DH Verwaltungs GmbH ("Zweite DH"), Dietmar Hopp, Oliver Hopp, and Daniel Hopp (collectively, the "Reporting DH-LT-Investments, and Dietmar Hopp are parties to the agreements with KfW described in Item 6 of this Schedule 13D relating to sition of the common shares of the Issuer. The Reporting Persons other than dievini, DH-LT-Investments, and Dietmar Hopp status as a "group" for purposes of this Schedule 13D.	
2)	Repres	sents	70,846,5	332 shares held of record by dievini.	
				alculated based on 187,120,718 common shares of CureVac N.V. outstanding as reported in its Form 20-F Annual Report filed with xchange Commission on April 28, 2022.	
				5	

1.		mes of etmar l		ing Persons.
2.	Ch (a) (b)	×	l(1)	priate Box if a Member of a Group (See Instructions)
3.	SE	C Use	Only	
4.	Sou PF	urce of	Funds	
5.	Ch	eck if I	Disclosı	rre of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) □
6.		izenshi rmany	-	ace of Organization
			7.	Sole Voting Power 158,700
Share Bene	ficiall		8.	Shared Voting Power 84,387,007 ⁽²⁾
Each Repo	rting		9.	Sole Dispositive Power 158,700
erso	n Wit	h	10.	Shared Dispositive Power 84,387,007 ⁽²⁾
11.	_	gregate 545,70		nt Beneficially Owned by Each Reporting Person
12.	Ch	eck if t	he Agg	regate Amount in Row (11) Excludes Certain Shares (See Instructions) \Box
13.		cent of 2% ⁽³⁾	f Class 1	Represented by Amount in Row (11)
14.	Ty _I		eportin	g Person (See Instructions)
E E t	Capita Beteili Person he vot	l Gmbl gunger is"). die ting an	H & Co n"), Zw evini, D d dispos	s filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-L KG ("DH-Capital"), DHFS II Holding GmbH & Co. KG ("DHFS II Holding"), OH Beteiligungen GmbH& Co. KG ("OH eite DH Verwaltungs GmbH ("DH Zweite"), Dietmar Hopp, Oliver Hopp, and Daniel Hopp (collectively, the "Reporting DH-LT-Investments, and Dietmar Hopp are parties to the agreements with KfW described in Item 6 of this Schedule 13D relating to sition of the common shares of the Issuer. The Reporting Persons other than dievini, DH-LT-Investments, and Dietmar Hopp catus as a "group" for purposes of this Schedule 13D.
				32 shares held of record by dievini, 10,102,286 shares held of record by DH-LT-Investments, 3,404,672 shares of record held by 517 shares held of record by a company of which Mr. Hopp is the sole shareholder.
				alculated based on 187,120,718 common shares of CureVac N.V. outstanding as reported in its Form 20-F Annual Report filed with schange Commission on April 28, 2022.

1.		Names of Reporting Persons. Oliver Hopp			
2.	Checl	k the Ap	prop	oriate Box if a Member of a Group (See Instructions)	
	(b)	$\Box^{(1)}$			
3.	SEC	Use Onl	ly		
4.	Source OO	ce of Fu	nds		
5.	Checl	k if Disc	closu	are of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e)	
6.	Citize Gern	_	r Pla	nce of Organization	
			7.	Sole Voting Power 0	
Share Benef	icially		8.	Shared Voting Power 70,846,532 ⁽²⁾	
Owne Each Repo	rting		9.	Sole Dispositive Power 0	
Perso	n With		10.	Shared Dispositive Power 70,846,532 ⁽²⁾	
11.		egate Aı 6 ,532⁽²⁾		nt Beneficially Owned by Each Reporting Person	
12.	Checl	k if the	Aggı	regate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13.	Perce 37.9 %		ass I	Represented by Amount in Row (11)	
14.	Type IN	of Repo	orting	g Person (See Instructions)	
E P tl	Capital C Beteiligu Persons" ne votin	GmbH 8 ingen"),). dievir g and di	z Co Zwe ni, D ispos	is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-LT-Investments"), DH-LT-Investments"), DH-LT-Investments"), DH-LT-Investments"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-LT-LT-Investments GmbH ("DH-LT-Investments"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-LT-Investments, the "Reporting H-LT-Investments and Dietmar Hopp are parties to the agreements with KfW described in Item 6 of this Schedule 13D relating to sition of the common shares of the Issuer. The Reporting Persons other than dievini, DH-LT-Investments, and Dietmar Hopp atus as a "group" for purposes of this Schedule 13D.	
2) F	Represen	nts 70,84	46,5 3	32 shares held of record by dievini.	
				lculated based on 187,120,718 common shares of CureVac N.V. outstanding as reported in its Form 20-F Annual Report filed with schange Commission on April 28, 2022.	

1.		es of Re	-	ing Persons.
2.	Check	k the A	ppro	priate Box if a Member of a Group (See Instructions)
	(b)	$\square^{(1)}$)	
3.	SEC U	Use Or	nly	
4.	Source OO	e of Fu	unds	
5.	Check	k if Dis	sclosı	are of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) \Box
6.	Citize Germ	_	or Pla	ace of Organization
			7.	Sole Voting Power 0
Numb Share: Senef			8.	Shared Voting Power 70,846,532 ⁽²⁾
Owne Each Repor	ting		9.	Sole Dispositive Power 0
Perso	n With		10.	Shared Dispositive Power 70,846,532 ⁽²⁾
11.		egate A 6,532 (2		nt Beneficially Owned by Each Reporting Person
12.	Check	k if the	Agg	regate Amount in Row (11) Excludes Certain Shares (See Instructions) \Box
13.	Percer 37.9 %		lass l	Represented by Amount in Row (11)
14.	Type (of Rep	ortin	g Person (See Instructions)
C B P tl	apital G eteiligu ersons" ne voting	GmbH (ingen")). dievi g and (& Co), Zw ini, D lispos	s filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH KG ("DH-Capital"), DHFS II Holding GmbH & Co. KG ("DHFS II Holding"), OH Beteiligungen GmbH& Co. KG ("OH eite DH Verwaltungs GmbH ("Zweite DH"), Dietmar Hopp, Oliver Hopp, and Daniel Hopp (collectively, the "Reporting oH-LT-Investments, and Dietmar Hopp are parties to the agreements with KfW described in Item 6 of this Schedule 13D relating to sition of the common shares of the Issuer. The Reporting Persons other than dievini, DH-LT-Investments, and Dietmar Hopp atus as a "group" for purposes of this Schedule 13D.
2) R	.epresen	its 70,8	346,5	32 shares held of record by dievini.
				alculated based on 187,120,718 common shares of CureVac N.V. outstanding as reported in its Form 20-F Annual Report filed with schange Commission on April 28, 2022.
				8

1.	Names of Reporting Persons. DHFS II Holding GmbH & Co. KG			
2.	(a)	$\boxtimes^{(1)}$	priate Box if a Member of a Group (See Instructions)	
	(b)			
3.	SEC U	Use Only		
4.	Source OO	e of Funds		
5.	Check	k if Disclos	are of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) \Box	
6.	Citize Germ	-	ace of Organization	
		7.	Sole Voting Power 0	
Share Benef	ficially	8.	Shared Voting Power 10,102,286 ⁽²⁾	
Each Repo	_	9.	Sole Dispositive Power 0	
Perso	n With	10.	Shared Dispositive Power 10,102,286 ⁽²⁾	
11.		egate Amou 2,286⁽²⁾	nt Beneficially Owned by Each Reporting Person	
12.	Check	k if the Agg	regate Amount in Row (11) Excludes Certain Shares (See Instructions) \square	
13.	Perce: 5.4%		Represented by Amount in Row (11)	
14.	Туре (ОО	of Reportin	g Person (See Instructions)	
C E P tl	Capital G Beteiligu Persons" he voting	SmbH & Co ngen"), Zw). dievini, E g and dispo	s filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-D. KG ("DH-Capital"), DHFS II Holding GmbH & Co. KG ("DHFS II Holding"), OH Beteiligungen GmbH& Co. KG ("OH eite DH Verwaltungs GmbH ("Zweite DH"), Dietmar Hopp, Oliver Hopp, and Daniel Hopp (collectively, the "Reporting DH-LT-Investments, and Dietmar Hopp are parties to the agreements with KfW described in Item 6 of this Schedule 13D relating to sition of the common shares of the Issuer. The Reporting Persons other than dievini, DH-LT-Investments, and Dietmar Hopp tatus as a "group" for purposes of this Schedule 13D.	
2) F	Represen	ts shares he	eld of record by DH-LT-Investments GmbH.	
			alculated based on 187,120,718 common shares of CureVac N.V. outstanding as reported in its Form 20-F Annual Report filed with schange Commission on April 28, 2022.	

1.	Names of Reporting Persons. Zweite DH Verwaltungs GmbH			
2.	(a)	⊠ (1)	priate Box if a Member of a Group (See Instructions)	
3.	(b) SEC U	□ Use Only		
4.	Source 00	e of Funds		
5.		if Disclos	are of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) \Box	
6.	Citizer Germ	-	ace of Organization	
		7.	Sole Voting Power 0	
Numb Shares Senef		8.	Shared Voting Power 3,404,672 ⁽²⁾	
Owne Each Repor	J	9.	Sole Dispositive Power 0	
Persor	n With	10.	Shared Dispositive Power 3,404,672 ⁽²⁾	
11.	Aggreg	-	nt Beneficially Owned by Each Reporting Person	
12.			regate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13.	Percen		Represented by Amount in Row (11)	
14.			g Person (See Instructions)	
C B Po	apital Gi eteiligun ersons"). the voti	mbH & Congen"), Zw dievini, C dievini, C	s filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT-Investments"), DH-LKG ("DH-Capital"), DHFS II Holding GmbH & Co. KG ("DHFS II Holding"), OH Beteiligungen GmbH& Co. KG ("OH eite DH Verwaltungs GmbH ("Zweite DH"), Dietmar Hopp, Oliver Hopp, and Daniel Hopp (collectively, the "Reporting DH-LT-Investments, and Dietmar Hopp, are parties to the agreements with KfW described in Item 6 of this Schedule 13D relating position of the common shares of the Issuer. The Reporting Persons other than dievini, DH-LT-Investments, and Dietmar Hopp tatus as a "group" for purposes of this Schedule 13D.	
2) R	epresent	s shares he	eld of record by Zweite DH Verwaltungs GmbH.	
			alculated based on 187,120,718 common shares of CureVac N.V. outstanding as reported in its Form 20-F Annual Report filed with schange Commission on April 28, 2022.	
			10	

This Amendment No. 6 to Schedule 13D (this "Amendment") amends the Schedule 13D filed with the Securities and Exchange Commission on August 24, 2020 by the Reporting Persons (the "Initial Statement" and, as amended and supplemented through the date of this Amendment, collectively, the "Statement") with respect to common shares, par value €0.12 per share (the "Shares") of CureVac N.V., a Dutch public company (the "Issuer").

The discussion of the Pooling Agreement in Item 6 of the Statement is amended to read as set forth in Item 6 of this Amendment to reflect its termination and Item 5 revised to reflect the impact of that event on the beneficial ownership of the Reporting Persons.

Item 5. Interest in Securities of the Issuer

(a) and (b) The information required by Items 5(a) and (b) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Pooling Agreement

dievini, DH-LT-Investments, MH-LT-Investments GmbH, Bohlini invest GmbH, and 4H invest GmbH were parties to a Pooling Agreement (the "Pooling Agreement") governing the disposition and voting of the Shares held by them. The Pooling Agreement was terminated on November 8, 2022.

Item 7. Materials to be Filed as Exhibits.

Exhibit No.	Description
1.	Power of Attorney (Incorporated by reference to Exhibit 1 to Amendment No. 5 to Schedule 13D filed by the Reporting Persons with the
	<u>SEC on May 5, 2022).</u>
2.	Joint Filing Agreement (Incorporated by reference to Exhibit 2 to Amendment No. 5 to Schedule 13D filed by the Reporting Persons with
	<u>the SEC on May 5, 2022).</u>

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 14, 2022

DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG

By: dievini Verwaltungs GmbH

its General Partner

By: /s/ Dr. Marc Hauser
Name: Dr. Marc Hauser
Title: Attorney-in-fact

DH-CAPITAL GMBH & CO. KG

By: DH Verwaltungs GmbH

its General Partner

By: /s/ Dr. Marc Hauser
Name: Dr. Marc Hauser
Title: Attorney-in-fact

OH BETEILIGUNGEN GMBH & CO. KG

By: OH Verwaltungs GmbH

its General Partner

By: /s/ Dr. Marc Hauser

Name: Dr. Marc Hauser Title: Attorney-in-fact

DH-LT-INVESTMENTS GMBH

By: /s/ Dr. Marc Hauser

Name: Dr. Marc Hauser Title: Attorney-in-fact

/s/ Dr. Marc Hauser as attorney-in-fact

DIETMAR HOPP

/s/ Dr. Marc Hauser as attorney-in-fact

OLIVER HOPP

/s/ Dr. Marc Hauser as attorney-in-fact

DANIEL HOPP

DFHS II GMBH & CO. KG

By: DHFS II GmbH

its General Partner

By: /s/ Dr. Marc Hauser
Name: Dr. Marc Hauser
Title: Attorney-in-fact

DH-LT-INVESTMENTS GMBH

y: /s/ Dr. Marc Hauser

Name: Dr. Marc Hauser
Title: Attorney-in-fact

ZWEITE DH VERWALTUNGS GMBH

/s/ Dr. Marc Hauser

Name: Dr. Marc Hauser Title: Attorney-in-Fact

By: